Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.9B | $766M | $241M | $509M | 3.3% | 3.7% | -10.8% |
| 2024 | $2.8B | $840M | $270M | $542M | 3.5% | 0.2% | -61.0% |
| 2023 | $2.8B | $714M | $693M | $10M | 8.8% | -16.9% | 21.8% |
| 2022 | $3.3B | $1.2B | $569M | $594M | 7.7% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 3,311.82 | 2,750.57 | 2,755.03 | 2,856.05 |
| Cost Of Revenue | - | 1,321.99 | 1,210.88 | 1,217.37 | 1,291.69 |
| Gross Profit | - | 1,989.83 | 1,539.69 | 1,537.66 | 1,564.36 |
| Operating Expense | - | 1,247.13 | 1,239.13 | 1,190.92 | 1,207.73 |
| Operating Income | - | 742.70 | 300.56 | 346.74 | 356.64 |
| EBITDA | - | 1,182.79 | 713.56 | 840.25 | 765.80 |
| EBIT | - | 755.79 | 281.79 | 412.40 | 360.46 |
| Pretax Income | - | 651.84 | 182.98 | 316.13 | 268.28 |
| Tax Provision | - | 139.16 | 3.47 | 33.06 | 28.39 |
| Net Income | - | 569.18 | 693.09 | 270.38 | 241.20 |
| Net Income Common Stockholders | - | 569.18 | 693.09 | 270.38 | 241.20 |
| Total Expenses | - | 2,569.12 | 2,450.01 | 2,408.28 | 2,499.42 |
| Interest Expense | - | 103.96 | 98.81 | 96.28 | 92.18 |
| Interest Income | - | 3.59 | 72.13 | 73.19 | 31.10 |
| Research And Development | - | 221.62 | 216.58 | 196.84 | 215.84 |
| Selling General And Administration | - | 1,025.51 | 1,022.55 | 994.07 | 991.89 |
| Normalized EBITDA | - | 1,206.45 | 785.46 | 839.27 | 792.21 |
| Normalized Income | - | 531.28 | 250.03 | 282.19 | 263.49 |
| Market Cap | 9,701.17 | 9,701.17 | 9,701.17 | 9,701.17 | 9,701.17 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Revvity, Inc.this co. | RVTY | $10.1B | 40.22β premium | 1.34 | 3.3% | 15.90 |
| Molina Healthcare, Inc. | MOH | $9.3B | 19.42 | 2.25 | 11.6% | 9.09 |
| Bio-Techne Corporation | TECH | $8.5B | 115.50 | 4.42 | 3.8% | 40.39 |
| Krystal Biotech, Inc. | KRYS | $7.9B | 39.16 | 6.58 | 16.8% | 44.89 |
| Alkermes plc | ALKS | $5.5B | 22.97 |
| - |
| - |
| - |
| - |
| 3.05 |
| 13.3% |
| 15.81 |
| PTC Therapeutics, Inc. | PTCT | $5.4B | 8.29 | -27.55 | -332.5% | 8.31 |
| TG Therapeutics, Inc. | TGTX | $5.3B | 13.08 | 9.02 | 69.0% | 44.82 |
| Apellis Pharmaceuticals, Inc. | APLS | $5.1B | 233.78 | 14.14 | 6.0% | 74.89 |
| Corcept Therapeutics Incorporated | CORT | $4.8B | 49.62 | 7.63 | 15.4% | 103.46 |
| Peer Median | - | 31.07 | 5.50 | 12.4% | 42.61 | |